Multiple myeloma is a type of cancer where plasma cells in bone marrow replicate out of control. Doctors use the acronym CRAB to diagnose myeloma by identifying four symptoms. The National Cancer ...

Legendary folk singer Sharda Sinha, known for her Chhath songs has died at the age of 72 years. The Padma Bhushan awardee was ...

Multiple myeloma is a rare blood cancer that affects your plasma cells. It makes up about 1.8% of all new cancer cases each year and about 10% of all blood cancers. You may not experience symptoms ...

And as myeloma cells continue to build up in the marrow, they weaken your bones, causing pain and fractures. Treatments for multiple myeloma target the cancer cells as well as the symptoms.

The department used its new system for determining whether a condition is service-connected to give affected veterans access ...

Sharda Sinha's battle with Multiple Myeloma highlights the disease's dangers. Learn about its impact and significance.- Watch ...

4, 2024 — A new study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma.

Non-secretory myeloma is a rare form of myeloma ... and does not cause paraprotein secretion easily misdiagnosed and has symptoms that overlap with various other conditions Researchers estimate ...

Kyphoplasty has also increasingly been used to treat vertebral osteolyses caused by multiple myeloma (MM ... neurologic symptoms, pulmonary embolism, and infections. Results: Painful osteolytic ...

It’s true that we’ve come a long way in recent years when it comes to treating multiple myeloma. More therapies are being developed, to the point where somebody diagnosed now is likely to have ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma ...